Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds expression product or fragment thereof of...
Patent
1993-12-30
2000-04-18
Burke, Julie
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds expression product or fragment thereof of...
4241391, 4241551, 4241741, 4241831, 4241471, 4241591, 435 696, 435 697, 435330, 435344, 5303911, 5303871, 5303888, 5303897, 5303873, A61K 39395, C07K 1630
Patent
active
060512261
ABSTRACT:
A new gene--MN--and proteins/polypeptides encoded therefrom are disclosed. Recombinant nucleic acid molecules for expressing MN proteins/polypeptides and fusion proteins are provided. Expression of the MN gene is disclosed as being associated with tumorigenicity, and the invention concerns methods and compositions for detecting and/or quantitating MN antigen and/or MN-specific antibodies in vertebrate samples that are diagnostic/prognostic for neoplastic and pre-neoplastic disease. Test kits embodying the immunoassays of this invention are provided. MN-specific antibodies are disclosed that can be used diagnostically/prognostically, therapeutically, for imaging, and/or for affinity purification of MN proteins/polypeptides. Also provided are nucleic acid probes for the MN gene as well as test kits comprising said probes. The invention also concerns vaccines comprising MN proteins/polypeptides which are effective to immunize a vertebrate against neoplastic diseases associated with the expression of MN proteins. The invention still further concerns antisense nucleic acid sequences that can be used to inhibit MN gene expression.
REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5387676 (1995-02-01), Zawada et al.
Uemura et al., "Expression of Tumor-Associated Antigen MN/G250 in Urologic Carcinoma: Potential Therapeutic Target," J. Urology: 157 (4 Supp): 377 (Abstract 1475) (Apr. 16, 1997).
Bander et al., "Renal cancer imaging with monoclonal antibody G250," Proc. Am. Urol. Assoc., 155 (Suppl.): 583A (Abstract 1088; May 1996).
Divgi et al., "Radioimmunotherapy with I-131-G250 in Metastatic Renal Cell Cancer (RCC)" J. Nucl. Med., 36 (5 Suppl.): 913P (Abstract 956; May 1995).
Liao et al., "Identification of the MN/CA9 Protein As a Reliable Diagnostic Biomarker of Clear Cell Carcinoma of the Kidney," Cancer Research, 57: 2827-2831 (Jul. 15, 1997).
McKiernan et al., "Expression of the Tumor-associated Gene MN: A Potential Biomarker for Human Renal Cell Carcinoma," Cancer Research 57: 2362-2365 (Jun. 15, 1997).
Oosterwijk and Debruyne, "Radiolabeled monoclonal antibody G250 in renal-cell carcinoma," World Journal of Urology, 13: 186-190 (1995).
Steffens et al., "Radioimmunotargeting of Renal Cell Carcinoma with I131 Labeled Chimeric G250 Monoclonal Antibody," J. Nucl. Med., 36 (5 Suppl.): 210P-211P (Abstract 946; May 19.
Turner et al., "MN Antigen Expression in Normal, Preneoplastic, and Neoplastic Esophagus: A Clinicopathological Study of a New Cancer-Associated Biomarker," Hum Pathol, 28(6): 740-744 (Jun. 1997).
Van Dijk et al., "Therapeutic Effects of Monoclonal Antibody G250, Interferons and Tumor Necrosis Factor, In Mice with Renal-Cell Carcinoma Xenografts," Int. J. Cancer, 56: 262-268 (1994).
Liao and Stanbridge, "Expression of the MN Antigen in Cervical Papanicolaou Smears Is an Early Diagnositc Biomarker of Cervical Dysplasia," Cancer Epidemiology, Biomarkers & Prevention, 5: 549-557 (Jul. 1996).
Divgi et al., "Scintigraphy of Renal Cell Carcinoma with I-131 Labelled Monoclonal Antibody (MAB) G250," European Journal of Nuclear Medicine, 19(8): 578 (Abstract) (Aug. 23, 1992).
Kurth et al., "Characterization of Human Renal Cell Carcinoma Tumor Lines by Means of Monoclonal Antibodies," Prostate, 6(4): 451 (Abstract) (1985).
Oosterwijk et al., "The Expression of Renal Antigens in Renal Cell Carcinoma," World Journal of Urology, 2(2): 156-158 (1984).
Oosterwijk et al., "Monoclonal Antibodies that Discriminate Between Renal Cell Carcinomas (RCC) and other Malignancies," Prostate, 6(4): 451-452 (1985).
Oosterwijk et al., "Immunohistochemical Analysis of Monoclonal Antibodies to Renal Antigens--Application in the Diagnosis of Renal Cell Carcinoma," American Journal of Pathology, 123(2): 301-309 (May 1986).
Oosterwijk et al., "Monoclonal Antibody G250 Recognizes a Determinant Present in Renal-Cell Carcinoma and Absent from Normal Kidney," Int. J. Cancer, 38: 489-494 (1986).
Oosterwijk et al., "Relationship Between DNA Ploidy, Antigen Expression and Survival in Renal Cell Carcinoma," Int. J. Cancer, 42: 703-708 (1988).
Oosterwijk et al., "Expression of Intermediate-sized Filaments in Developing and Adult Human Kidney and Renal Cell Carcinoma," The Journal of Histochemistry and Cytochemistry, 38(3): 385-392 (1990).
Oosterwijk et al., "Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250," Journal of Clinical Oncology, 11(4): 738-750 (Apr. 1993).
Oosterwijk et al., "Molecular characterization of the Renal Cell Carcinoma-associated antigen G250," Proceedings of the American Association for Cancer Research, 37: 461 (Mar. 1996).
Svoboda, J., National Cancer Center Institute Monograph No. 17, "Malignant Interaction of Rous Virus with Mammalian Cells In Vivo and In Vitro," In: International Conference on Avian Tumor Viruses (J.W. Beard, ed.), pp. 277-298 (1964).
Taylor et al., "Major Histocompatibility (B) Complex Control of the Growth Pattern of v-src DNA-Induced Primary Tumors," Virology, 191: 477-479 (1992).
Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer," PNAS (USA), 85: 8998-9002 (Dec. 1988).
Drebin et al., "Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen," PNAS (USA) 33: 9129-9133 (Dec. 1986).
Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo," Oncogene, 2: 273-277 (1988).
Drebin et al., "Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo," Oncogene, 2: 387-394 (1988).
Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic," Journal of Clinical Immunology, 11(3): 117-127 (1991).
Frosch et al., "Cloning and Characterisation of an Immunodominant Major Surface Antigen of Echinococcus multilocularis", Molecular and Biochemical Parasitology, 48: 121-130 (1991).
Pastorekova et al., "A Novel Quasi-viral Agent, MaTU, Is a Two-Component System", Virology, 187: 620-626 (1992).
Stanbridge et al., "Specific Chromosome Loss Associated with the Expression of Tumorigenicity in Human Cell Hybrids", Somatic Cell Genetics, 7(6): 699-712 (1981).
Stanbridge et al., "Human Cell Hybrids: Analysis of Transformation and Tumorigenicity", Science, 215: 252-259 (Jan. 15, 1982).
Tweedie and Edwards, "Mouse Carbonic Anhydrase III: Nucleotide Sequence and Expression Studies", Biochemical Genetics, 27(1/2): 17-30 (1989).
Young and Davis, "Efficient Isolation of Genes by Using Antibody Probes", PNAS (USA) 80: 1194-1198 (Mar. 1983).
Zavada, "The Pseudotypic Paradox", J. gen. Virol., 63: 15-24 (1982).
Zavada and Zavadova, "A Transmissible Antigen Detected in Two Cell Lines Derived from Human Tumours", J. gen. Virol., 24: 327-337 (1974).
Zavada and Zavadova, "An unusual transmissible agent--MaTu", Arch. Virol., 118: 189-197 (1991).
Zavada et al., "VSV Pseudotype Produced in Cell Line derived from Human Mammary Carcinoma", Nature New Biology, 240: 124-125 (Nov. 22, 1972).
Zavada et al., "Tumorigenicity-Related Expression of MaTu Proteins in HeLa x Fibroblast Hybrids", Abstract presented at the XIX Meeting of the European Tumor Virus Group (May 1-4, 1991).
Zavada et al., "Expression of MaTu-MN Protein in Human Tumor Cultures and in Clinical Specimens", Int. J. Cancer, 54: 268-274 (1993).
Queen, C. et al. (1989) A Humanized Antibody that Binds to the Interleukin 2 Receptor. Proc. Natl. Acad. Sci USA vol. 86, p. 10029-10033.
Blakey, D.C. et al. (1988) Antibody Toxin Conjugates: A Perspective. Monoclonal Antibody Therapy. Prog Allergy vol. 45 pp. 50-90.
Osband, ME and Ross S. (1990) Immunology Today vol. 11 No. 6. p. 193-195.
Waldmann, T.A. (1991) Monoclonal Antibodies in Diagnosis and Therapy. Science vol. 252 p. 1657-1662.
Dillman, R.O. (1989). Monoclonal Antibodies for Treating Cancer. Annals of Internal Medicine vol. 111 p. 592-603.
Hird, V. et al. (1990). Immunotherpay with Monoclonal Antibodies. Genes and Cancer Chapte
Pastorek Jaromir
Pastorekova Silvia
Zavada Jan
Burke Julie
Institute of Virology Slovak Academy of Sciences
Lauder Leona L.
Morgenstern Arthur S.
LandOfFree
MN-specific antibodies and their use in cancer treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MN-specific antibodies and their use in cancer treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MN-specific antibodies and their use in cancer treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2334409